Adults aged 18-45 years , children aged 24-59 months , older infants aged 9-12 months , and infants aged 6-8 weeks were randomly assigned ( 1:1 ) with a computer-generated randomisation list ( block size of four ) to receive either 5 g Vi-CRM197 or 25 g Vi-polysaccharide vaccine ( or 13-valent pneumococcal conjugate vaccine in children younger than 2 years ) .